- Home
- MBRX vs NRXS Comparison
MBRX vs NRXS Comparison
Compare MBRX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- NRXS
- Stock Information
- Founded
- MBRX 2015
- NRXS 2011
- Country
- MBRX United States
- NRXS United States
- Employees
- MBRX N/A
- NRXS N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- MBRX Health Care
- NRXS
- Exchange
- MBRX Nasdaq
- NRXS Nasdaq
- Market Cap
- MBRX 11.3M
- NRXS 12.5M
- IPO Year
- MBRX 2016
- NRXS 2023
- Fundamental
- Price
- MBRX $1.11
- NRXS $2.39
- Analyst Decision
- MBRX Strong Buy
- NRXS
- Analyst Count
- MBRX 2
- NRXS 0
- Target Price
- MBRX $6.00
- NRXS N/A
- AVG Volume (30 Days)
- MBRX 338.4K
- NRXS 38.4K
- Earning Date
- MBRX 05-09-2025
- NRXS 05-21-2025
- Dividend Yield
- MBRX N/A
- NRXS N/A
- EPS Growth
- MBRX N/A
- NRXS N/A
- EPS
- MBRX N/A
- NRXS N/A
- Revenue
- MBRX N/A
- NRXS $2,685,925.00
- Revenue This Year
- MBRX N/A
- NRXS $138,883.78
- Revenue Next Year
- MBRX N/A
- NRXS $118.59
- P/E Ratio
- MBRX N/A
- NRXS N/A
- Revenue Growth
- MBRX N/A
- NRXS 9.18
- 52 Week Low
- MBRX $0.40
- NRXS $1.33
- 52 Week High
- MBRX $5.47
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- MBRX 58.77
- NRXS 64.43
- Support Level
- MBRX $0.80
- NRXS $1.33
- Resistance Level
- MBRX $1.05
- NRXS $2.55
- Average True Range (ATR)
- MBRX 0.10
- NRXS 0.36
- MACD
- MBRX 0.04
- NRXS 0.08
- Stochastic Oscillator
- MBRX 100.00
- NRXS 86.48
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).